

MarketVue®

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

July 2022



MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy

UNDERSTAND THE CIDP MARKET

MarketVue market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Methodology: Research is supported by 10 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research. Qualitative interview participants included 4 U.S. Neurologists, 4 EU Neurologists, and 2 Japan Neurologists.

Geographies covered: United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom) and Japan.

TOPICS COVERED

EPIDEMIOLOGY: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

CURRENT TREATMENT: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

UNMET NEEDS: Identify opportunities to address treatment or disease management gaps

PIPELINE ANALYSIS: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

VALUE AND ACCESS: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy

UNDERSTAND THE CIDP MARKET

COMPANIES MENTIONED

- Sanofi
- Argenx
- Janssen Pharmaceuticals
- UCB
- Takeda Pharmaceuticals

DRUGS MENTIONED

- IVIg (HyQvia)
- Rituximab
- SAR445088
- Efgartigimod (Vyvgart)
- Nipocalimab
- Rozanolixizumab (Rystiggo)

MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy

Table of Contents

1. DISEASE OVERVIEW	5 - 6
A rare, autoimmune neurological disorder characterized by loss of sensation and motor weakness	5
Figure 1.1. Clinical presentation of CIDP	5
CIDP is characterized by motor and/or sensory deficits	6
Table 1.1. CIDP – Typical and atypical variants	6
Figure 1.2. Neurologist-reported segmentation of their CIDP patient population	6
Figure 1.3. Neurologist-reported percentage of patients previously misdiagnosed, incorrectly diagnosed, or not diagnosed in a timely manner	6
2. EPIDEMIOLOGY & PATIENT POPULATIONS	7
Disease definition	7
Figure 2.1 – G7 diagnosed prevalent cases of CIDP by region	7
Table 2.1 – Diagnosed prevalent and drug-treated patients in the G7	7
3. DIAGNOSIS AND CURRENT TREATMENT	8 - 19
Diagnosis Overview	8
Figure 3.1. Diagnostic criteria for CIDP based on EFNS/PNS guidelines	8
Physician insights on diagnosis of CIDP	9
Majority of CIDP patients require drug treatment	10
Treatment Overview	10
Figure 3.2. Treatment goals for CIDP	10
Figure 3.3. Neurologist-reported percentage of patients receiving some form of drug therapy	10
Treatment flow for CIDP	11
Figure 3.4. Treatment algorithm for CIDP	11
Immunoglobulin therapy is the standard of care	12
Figure 3.5. Current Treatment Patient Share	12
Figure 3.6. Neurologist (n=26) rating of current effective therapy effectiveness in CIDP	12
Upsides and downsides of current CIDP treatments	13
Neurologists' perspectives on current treatments	14
IVIg is an effective and safe front-line treatment	15
Figure 3.7. IVIg's advantages observed in clinical practice	15

MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy

Table of Contents

IVIg therapy is not without challenges	16
Figure 3.8. Approximately 30% of IVIg-treated patients have a poor/inadequate response/are refractory to IVIg therapy	16
Key treatment dynamics that shape disease management and drug use in CIDP	17
Figure 3.9. Must-know CIDP treatment dynamics for now and the future	17
Immunomodulating therapies are the future of CIDP therapy	18
Figure 3.10. Important dynamics of CIDP market evolution	18
4. UNMET NEED	19 - 21
Overview	19
Figure 4.1. Top unmet needs in CIDP	19
Figure 4.2. Physician-reported unmet needs in CIDP	19
Barriers to care – Physician perspectives	20
Figure 4.3. Percent of patients who see these factors as barriers to receiving drug therapy	20
Physician perspectives on unmet needs in CIDP	21
Figure 4.4. U.S. neurologists' ranking of the need for new treatments in CIDP	21
5. PIPELINE ANALYSIS	22 - 24
Overview	22
Figure 5.1. Number of emerging therapies with clinical trial endpoints that align with unmet needs in CIDP	22
Table 5.1. Comparison of emerging therapy MoAs	22
The pipeline for CIDP is active with multiple treatments in late-stage trials	23
Table 5.2. Comparison of ongoing trials of therapies for CIDP	23
Although emerging therapies with novel mechanisms are exciting, they may not replace IVIg	24
Figure 5.2. Percentage of neurologists who rated the following emerging target or approach as “promising” ¹	24
6. VALUE & ACCESS	25 - 26
Overview	25
Table 6.1 – Current therapy pricing	25
Table 6.2. Typical commercial payer coverage of IV Immune Globulin and Subcutaneous Immune Globulin (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)	25
Key market access dynamics that will continue to shape treatment use	26
Figure 6.2. Physician-reported key barriers to drug therapy for CIDP patients	26

MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy

Table of Contents

7. METHODOLOGY

27 - 28

Primary market research approach

27

Epidemiology methodology

28

Meet the REACH Team



DANIELLE DRAYTON, PhD., Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



MELISSA CURRAN is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



MICHAEL HUGHES, MSc, Ph.D., Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

Meet the REACH Team



TYLER JAKAB, MPH is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



BAYLEY KOOPMAN is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



BRIANA MULLINS is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.